Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DuoGenic StemCellsROCO:7607 -0.76%25 Current Ratio is 2.24 as of Dec. 2025, which is 65% below its 10-year median of 6.44. GuruFocus rates ROCO:7607 with a GF Score™ of 25/100 and a GF Value™ of NT$51.22 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 1,410 Biotechnology companies, DuoGenic StemCells ranks worse than 65.04% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. DuoGenic StemCells's current ratio for the quarter that ended in Dec. 2025 was 2.24.
DuoGenic StemCells has a current ratio of 2.24. It generally indicates good short-term financial strength.
The historical rank and industry rank for DuoGenic StemCells's Current Ratio or its related term are showing as below:
ROCO:7607'
s Current Ratio Range Over the Past 10 Years
Min: 0.96 Med: 6.44 Max: 15.19
Current: 2.24
During the past 5 years, DuoGenic StemCells's highest Current Ratio was 15.19. The lowest was 0.96. And the median was 6.44.
ROCO:7607's Current Ratio is ranked worse than 65.04% of 1410
companies
in the Biotechnology industry
Industry Median: 3.88
vs ROCO:7607: 2.24
DuoGenic StemCells (ROCO:7607) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
DuoGenic StemCells Current Ratio Related Terms
DuoGenic StemCells Current Ratio Historical Data
* Premium members only.
The historical data trend for DuoGenic StemCells's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7607 vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, DuoGenic StemCells's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DuoGenic StemCells Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, DuoGenic StemCells's Current Ratio distribution charts can be found below:
* The bar in red indicates where DuoGenic StemCells's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DuoGenic StemCells (ROCO:7607) has a Current Ratio of 2.24 as of Dec. 2025. This is 65% below median its historical median of 6.44. Over the past decade, DuoGenic StemCells' Current Ratio has ranged from 0.96 to 15.19. According to the industry distribution chart, DuoGenic StemCells ranks #917 out of 1410 companies in the Biotechnology industry, placing it in the top 65%.
Is DuoGenic StemCells' Current Ratio too high?
DuoGenic StemCells' current Current Ratio of 2.24 is 65% below median its 10-year median of 6.44. Over the past 10 years, this metric has ranged from a low of 0.96 to a high of 15.19. The Biotechnology industry median Current Ratio is 3.88. DuoGenic StemCells' value of 2.24 is 42.3% below this industry median. Based on the distribution chart, DuoGenic StemCells ranks #917 out of 1410 companies in the Biotechnology industry, which is below the industry midpoint. Overall, DuoGenic StemCells has a GF Score™ of 25/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does DuoGenic StemCells' Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, DuoGenic StemCells ranks #917 out of 1410 companies for Current Ratio. This places DuoGenic StemCells in the lower half of its industry. The industry median Current Ratio is 3.88. DuoGenic StemCells' value of 2.24 is 42.3% below this benchmark. Historically, DuoGenic StemCells' own Current Ratio has ranged from 0.96 to 15.19 over the past decade. While the company's 10-year median is 6.44 vs. the industry median of 3.88, DuoGenic StemCells has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.88, based on 1,410 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DuoGenic StemCells's current Current Ratio of 2.24 is 42.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DuoGenic StemCells's current Current Ratio is 2.24, which is 65% below median its own 10-year median of 6.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DuoGenic StemCells stock overvalued right now?
Based on GuruFocus' analysis, DuoGenic StemCells (ROCO:7607) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$51.22, compared to a current price of NT$13.00 — trading 74.6% below its estimated fair value. The current Current Ratio is 2.24, which is 65% below median its 10-year median of 6.44 and 42.3% below the Biotechnology industry median of 3.88. DuoGenic StemCells' overall GF Score™ is 25/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For DuoGenic StemCells (ROCO:7607), the current Current Ratio is 2.24 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DuoGenic StemCells (ROCO:7607) Overvalued in 2026?
Based on GuruFocus' analysis, DuoGenic StemCells stock appears to be undervalued.
The current stock price of NT$13.00 is trading 74.6% below its estimated GF Value™ of NT$51.22.
GuruFocus considers DuoGenic StemCells to be Significantly Undervalued.
Key valuation signals for ROCO:7607:
Current Ratio: 2.24 (65% below median its 10-year median of 6.44)
GF Value™: NT$51.22 vs. price of NT$13.00 (74.6% below fair value)
Industry Position: 42.3% below the Biotechnology median (#917 of 1410)
No single metric tells the full story. See the ROCO:7607 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DuoGenic StemCells Corp is a company having a team of passionate researchers focused on stem cell cultivation. Their products are intended for research use and can be upgraded for clinical applications. It also develops blood cell therapy programs, using the isolation and purification of blood mononuclear cells to remove granule cells that promote inflammation, and conducts clinical trials on various degenerative diseases to provide a convenient and simple new option for cell therapy.
25GF Score
Get the complete analysis for ROCO:7607
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7607 has been successfully added to your 
